Table 1.
Patient characteristics and transplant outcomes
| Characteristics | LRTD RV (n = 98) | Bacterial pneumonia (n = 19) | P |
|---|---|---|---|
| Age (y), median (range) | 0 | 48 (35‐70) | .7 |
| Male sex, n (%) | 55 (56) | 13 (68) | .4 |
| Baseline disease, n (%) | |||
| AL/MDS/MPN/AA | 43 (44)/5 (5)/6 (6)/1 (1) | 7 (37)/1 (5)/2 (10)/1 (5) | .8 |
| NHL/HL/CLL/MM | 20 (20)/5 (5)/15 (15)/3 (4) | 5 (26)/1 (5)/2 (10)/0 | |
| Disease status at transplant, n (%) | |||
| CR/Untreated | 61 (62)/6 (6) | 11 (58)/4 (20) | .8 |
| PR | 19 (19) | 2 (10) | |
| Refractory/active disease | 11 (11) | 3 (16) | |
| Prior ASCT, n (%) | 24 (24) | 5 (26) | .2 |
| Conditioning regimen, n (%) | |||
| RIC | 55 (56) | 11 (58) | .9 |
| Myeloablative | 43 (44) | 8 (42) | |
| Type of donor, n (%) | |||
| HLA‐identical sibling donor | 26 (26) | 9 (47) | .2 |
| Unrelated donor | 24 (24) | 4 (21) | |
| Umbilical cord blood | 28 (28) | 1 (5) | |
| Haploidentical family donor | 20 (20) | 5 (26) | |
| HLA fully matched, n (%) | 38 (38) | 10 (53) | .9 |
| ATG as a part of the conditioning, n (%) | 40 (40) | 4 (21) | .7 |
| Recipient and/or donor CMV seropositive, n (%) | 86 (88) | 17 (90) | .9 |
| GvHD prophylaxis, n (%) | |||
| Sir‐Tac | 17 (17) | 5 (26) | .7 |
| CsA + MTX | 23 (23) | 8 (42) | |
| Post‐CyPh | 25 (30) | 5 (26) | |
| CsA + PDN/Others | 27 (27)/6 (6) | 1 (5) | |
| Post‐transplant outcome | |||
| GvHD at the time of BAL, n (%) | 59 (59) | 10 (53) | .6 |
| Acute grade II‐IV | 29 (29) | 5 (26) | |
| Chronic | 30 (30) | 6 (32) | |
| Overall mortality by day 60 after BAL, n (%) | 33 (33%) | 7 (37) | .5 |
| Median time from allo‐HSCT to LRTD, days (range) | 145 (0‐1568) | 174 (5‐6700) | .4 |
| LRTD type, n (%) | |||
| CARV mono‐infection | 52 (52) | ||
| Viral co‐infection | 15 (15) | ||
| Bacterial co‐infection | 20 (20) | ||
| Fungal co‐infection | 11 (11) | ||
| Bacterial mono‐infection | 23 (100) | ||
| Admission ICU, n (%) | 26 (26) | 10 (53) | .1 |
| Median F‐Up after BAL for survivors, days (range) | 267 (62‐2230) | 207 (60‐1387) | .6 |
AA, aplastic anemia; AL, acute leukemia; allo‐HSCT, allogeneic hematopoietic stem cell transplantation; ASCT, autologous stem cell transplantation; ATG, anti thymocytic globulin; BAL, bronchoalveolar lavage; CARV, community acquired respiratory virus; CLL, chronic lymphocytic leukemia; CR, complete remission; CsA, cyclosporine A; F‐up, follow‐up; GvHD, graft versus host disease; HLA, human leukocyte antigen; HL, Hodgkin lymphoma; ICU, intensive care unit; LRTD RV, lower respiratory tract disease by respiratory viruses; MDS, myelodysplastic syndrome; MM, multiple myeloma; MPN, myeloproliferative neoplasm; MTX, methotrexate; NHL, non‐Hodgkin's lymphoma; PDN, prednisone; Post‐CyPh, post‐transplant cyclophosphamide; PR, partial remission; RIC, reduced intensity conditioning; Sir, sirolimus; Tac, tacrolimus.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.